Now Avid Bioservices CDMO captures attention of-IIS
G-no, I don't know why some IIS would take chances at this time but we shall see
This has been one hell of a journey for sure where every so often Peregrine Pharmaceuticals PPHM - now Avid Bioservices CDMO was in fact, a true war for the IP that took many down the road where we seen enough ...just enough to wonder why strange things happened yet those involved always landed up right with patents bought out / newer better jobs / companies bought out and all the facts have not been allowed yet
Avid Bioservices has a CDMO I like no other and the IP assets are still in line as long as Ampersand knows how to play it from now on
The IIS Institutional investors are now at their peak and thanks to CJ for the compilation of reports which should be read over carefully as the drop in price Friday was fabricated and now, there will be some IIS that can really start picking up the final round of loose shares
I have been asked not to mention certain info but I refuse to not post some info that will lead some to probably regret taking paths that may not be so legal
Daniel Cua poached over to Janssen from Merck very recently and I wonder if Ampersand will go public with some info they have and/or Avid
_____
Remember the name â??Jenna Markâ? that is now with Ampersand Capital
Jenna worked in the Folker Lab at Boston College / that would be Eric S. Folker
This is important because the working lab with knowledge of IP assets re: PtdSer (Phosphatidylserine)
Next everyone will be introduced to Kathryn Packman that is Janssen (JNJ) ex marriage now â??-to Eric S Folker
As Big Pharma is up against Big Pharma.... IIS is pitted against MANY other IIS that is soon getting the information they need
Boston College on that FBI list of emails being watched as MD Anderson and Memorial Sloan Kettering ? I would say yes
Maybe we get some surprise news finally this week after an awful performance on that cc
Much more to come ....
____
Kathryn Packman
Sr. Scientific Director and Global Head of Tumor Biology at Janssen Pharmaceutical Companies of Johnson & Johnson
Greater Boston Area
Senior Scientific Director, Tumor Biology
Janssen Pharmaceutical Companies of Johnson & Johnson
September 2015 â?? Present 4 years 1 month
Cambridge, MA
Image for Scientific Director Oncology Collaborations
Scientific Director Oncology Collaborations
Janssen Pharmaceutical Companies of Johnson & Johnson
October 2013 â?? August 2015 1 year 11 months
Cambridge, MA
Image for Roche Translational Clinical Research Center, Inc.
Roche Translational Clinical Research Center, Inc.
11 years 6 months
Head of Preclinical Oncology Research
October 2012 â?? September 2013 1 year
New York, NY
Appointed to define strategies and deliver preclinical research support to the Global Oncology R&D head, head of Translational Medicine, and USA head of Academic Alliances.
â?¢ Ensure strategic alignment between research and exploratory development
â?¢ Initiate, maintain and optimize preclinical collaborations with academic and biotech partners
â?¢ Evaluate therapeutic and technology opportunities for partnering, academic alliances, and
venture capital
â?¢ Represent Roche in academic collaborations on Joint Research Committees with leading
academic cancer research centers
â?¢ Lead platform-based biology efforts for added value to global oncology programs
â?¢ Responsible for preclinical research study design and implementation, data evaluation, reporting
and regulatory documentation
â?¢ Represent the Oncology Disease Therapeutic Area (Oncology DTA) on the TCRC Leadership
Team
â?¢ Represent the TCRC site on the Global DTA Oncology Management Team
Head of Tumor Biology/ In Vivo Pharmacology
April 2002 â?? October 2012 10 years 7 months
Nutley, NJ
Led 12 scientists (3 Ph.D.) in preclinical in vivo pharmacology research in support of all Oncology projects, including small molecules, biologics, RNAi, and peptides.
â?¢ Oversaw development of rodent models of cancer including subcutaneous and orthotopic xenografts from established solid or hematological cell lines, patient-derived xenografts, allografts, experimental metastasis and genetically engineered models, bioluminescence and fluorescence imaging
â?¢ Led team for pharmacokinetic, antitumor efficacy and biomarker studies to support all site oncology projects
â?¢ Contributed key data for the development of 10 clinical candidates
â?¢ Contributed towards preclinical modeling of dose-dense regimen for capecitabine under clinical investigation for metastatic breast cancer
â?¢ Project Leader for RO5486055, a humanized Hepsin neutralizing antibody for treatment of prostate and breast cancer reaching Clinical Lead stage
â?¢ Member of Roche Global and Nutley Site Discovery Oncology Leadership Teams
â?¢ Core member of Target Identification team with significant input into strategy and target selection
â?¢ Contributed guidance and decision-making to Oncology portfolio, in-licensing opportunities (therapeutics or technologies) and department staffing
â?¢ Represented preclinical tumor biology on early clinical development teams
â?¢ Member of joint project teams with external partners
â?¢ Initiated and managed academic collaborations and contract research
â?¢ Managed internal and outsourcing budget for in vivo pharmacology studies and technology licensing
â?¢ Authored and amended animal research protocols to support preclinical oncology research studies
â?¢ 9 year member of Institutional Animal Care and Use Committee (Chair for 3 yrs)
â?¢ Member of Roche Global Ethics Committee, with remit to review and approve all non-human primate
Adjunct Professor
UMDNJ
2003 â?? 2013 10 years
Postdoctoral Fellow
University of Notre Dame
2000 â?? 2002 2 years
South Bend, Indiana
People also viewed
Priyanka Nair-Gupta, Ph.D
Senior Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson
Deborah Ricci
Sr. Director, Translation Research at Janssen
Jonathan Branch
Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson
Sheri Moores
Director at Janssen Research & Development
Douglas Dolfi
Scientific Leader Translational Science Immuno-Oncology at GSK
Natalie Hutnick, Ph.D.
Director Scientific Licensing at The Janssen Pharmaceutical Companies of Johnson & Johnson
Diana Alvarez Arias
Senior Scientist at Janssen, Pharmaceutical Companies of Johnson and Johnson
Yingzhe (Angela) Li
Senior scientist, CAR-T/T cell redirection Oncology, project leader, Johnson & Johnson
Nader Fotouhi
Vani Lakshminarayanan
Biomarker Research Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson
